How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) issued its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analyst estimates of $8.12 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include bluebird bio (BLUE) , Sorrento Therapeutics (SRNE) , Amicus Therapeutics (FOLD) , Novavax (NVAX) , Rigel Pharmaceuticals (RIGL) , Inovio Pharmaceuticals (INO) , OPKO Health (OPK) , TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX) .

NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free KIN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $9.24
▼
$9.26
50-Day Range: $9.08
▼
$9.25
52-Week Range: $3.46
▼
$9.28

Volume: 178,496 shs
Average Volume: 840,890 shs
Market Capitalization: $420.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Kindred Biosciences alerts:

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Kindred Biosciences Stock (NASDAQ:KIN)

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

KIN Stock News Headlines

March 22, 2024 | mirror.co.uk

Tory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire Police

February 23, 2024 | health.usnews.com

Kindred Hospital East Greensboro

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

January 22, 2024 | reuters.com

Japan's Sony terminates $10 bln Zee India merger

January 22, 2024 | markets.businessinsider.com

European Shares Edge Higher With ECB Meeting In The Spotlight

January 22, 2024 | markets.businessinsider.com

Earnings Optimism May Contribute To Continued Strength On Wall Street

December 17, 2023 | latimes.com

Honoree: Nanxi Liu

November 8, 2023 | finance.yahoo.com

Global Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

October 7, 2023 | health.usnews.com

Kindred Hospital-Dayton

September 21, 2023 | tmcnet.com

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

August 17, 2023 | bizjournals.com

How a small Peninsula company plans to take a big bite out of the pet drug market

June 11, 2023 | es-us.finanzas.yahoo.com

Pet Cancer Therapeutics Global Market Report 2023

May 11, 2023 | marketwatch.com

Oral COVID-19 Vaccine Market 2023 Expected Highest Growth and Precise Outlook | Pfizer, CanSino Biologics, Kindred Biosciences

May 5, 2023 | marketwatch.com

Pet Medication Market Size and Forecast to 2031

May 5, 2023 | health.usnews.com

Kindred Hospital-New Jersey Morris County

April 26, 2023 | uk.finance.yahoo.com

Veterinary Dermatology Drugs Global Market Report 2023

April 25, 2023 | health.usnews.com

Kindred Hospital Chicago-Northlake

April 19, 2023 | usnews.com

Kindred High School

April 19, 2023 | thestreet.com

Kindred Bio CEO: Expect 3 Dynamic Dog Drugs by 2015

March 31, 2023 | theguardian.com

Kindred review – a reductive, hollow view of Black trauma

March 30, 2023 | marketwatch.com

Canine Atopic Dermatitis Market Share and Forecast till 2031

March 28, 2023 | health.usnews.com

Kindred Hospital-Ontario

March 22, 2023 | marketwatch.com

Companion Animal Pharmaceuticals Market worth $19.6 billion | MarketsandMarkets

March 7, 2023 | marketwatch.com

The Pet Medication study examines a number of direct and indirect factors that could affect the supply and demand dynamics in this market

March 6, 2023 | msn.com

How De La Soul's 3 Feet High and Rising broadened the possibilities of hip hop

March 3, 2023 | marketwatch.com

Pet Medication Market 2023 | Global Industry Report Forecast 2029

See More Headlines

Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/05/2021
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KIN
CUSIP: N/A
CIK: 1561743
Web: kindredbio.com
Phone: (650) 701-7901
Fax: N/A
Employees: 63
Year Founded: 2013

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,800,000.00
Net Margins: -529.26%
Pretax Margin: N/A
Return on Equity: -54.19%
Return on Assets: -39.76%

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 7.02
Quick Ratio: 7.02

Sales & Book Value

Annual Sales: $42.16 million
Price / Sales: 9.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.75 per share
Price / Book: 5.29

Miscellaneous

Outstanding Shares: 45,462,000
Free Float: N/A
Market Cap: $420.52 million
Optionable: Optionable
Beta: 1.30

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Richard H. Chin
President, Chief Executive Officer & Director
Wendy Wee
Secretary, Chief Financial & Accounting Officer
Hangjun Zhan
Chief Scientific Officer
Russell Radefeld
VP-Information Technology & Digital Marketing
Jay Peterson
Senior Director-Biomanufacturing

Key Competitors

View All Competitors

KIN Stock Analysis - Frequently Asked Questions

How were Kindred Biosciences' earnings last quarter?: Kindred Biosciences, Inc. (NASDAQ:KIN) issued its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analyst estimates of $8.12 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.
What other stocks do shareholders of Kindred Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

This page (NASDAQ:KIN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kindred Biosciences (KIN) Stock Price, News & Analysis

About Kindred Biosciences Stock (NASDAQ:KIN)

KIN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

KIN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info